Director/PDMR Shareholding

RNS Number : 5449W

GlaxoSmithKline PLC

09 February 2017

 

GlaxoSmithKline plc (the 'Company')

Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Sir Philip Hampton
b)	Position/status	Non-Executive Chairman
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Acquisition of notional Ordinary Shares following the annual reinvestment of dividends paid to shareholders throughout 2016 under the share allocation arrangements for Independent Non-Executive Directors.
c)	Price(s) and volume(s)	Price(s) Volume(s) £15.55 924.285
d)	Aggregated information Aggregated volume Price	n/a (single transaction)
e)	Date of the transaction	2017-02-08
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Professor Sir Roy Anderson
b)	Position/status	Independent Non-Executive Director
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Acquisition of notional Ordinary Shares following the annual reinvestment of dividends paid to shareholders throughout 2016 under the share allocation arrangements for Independent Non-Executive Directors.
c)	Price(s) and volume(s)	Price(s) Volume(s) £15.55 1,850.161
d)	Aggregated information Aggregated volume Price	n/a (single transaction)
e)	Date of the transaction	2017-02-08
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr Vindi Banga
b)	Position/status	Senior Independent Non-Executive Director
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Acquisition of notional Ordinary Shares following the annual reinvestment of dividends paid to shareholders throughout 2016 under the share allocation arrangements for Independent Non-Executive Directors.
c)	Price(s) and volume(s)	Price(s) Volume(s) £15.55 271.263
d)	Aggregated information Aggregated volume Price	n/a (single transaction)
e)	Date of the transaction	2017-02-08
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Dr Vivienne Cox
b)	Position/status	Independent Non-Executive Director
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Acquisition of notional Ordinary Shares following the annual reinvestment of dividends paid to shareholders throughout 2016 under the share allocation arrangements for Independent Non-Executive Directors.
c)	Price(s) and volume(s)	Price(s) Volume(s) £15.55 3.951
d)	Aggregated information Aggregated volume Price	n/a (single transaction)
e)	Date of the transaction	2017-02-08
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Ms Lynn Elsenhans
b)	Position/status	Independent Non-Executive Director
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	American Depositary Shares ('ADSs') ISIN: US37733W1053
b)	Nature of the transaction	Acquisition of notional ADSs following the annual reinvestment of dividends paid to shareholders throughout 2016 under the share allocation arrangements for Independent Non-Executive Directors.
c)	Price(s) and volume(s)	Price(s) Volume(s) $39.46 1,177.411
d)	Aggregated information Aggregated volume Price	n/a (single transaction)
e)	Date of the transaction	2017-02-08
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Ms Judy Lewent
b)	Position/status	Independent Non-Executive Director
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	American Depositary Shares ('ADSs') ISIN: US37733W1053
b)	Nature of the transaction	Acquisition of notional ADSs following the annual reinvestment of dividends paid to shareholders throughout 2016 under the share allocation arrangements for Independent Non-Executive Directors.
c)	Price(s) and volume(s)	Price(s) Volume(s) $39.46 626.140
d)	Aggregated information Aggregated volume Price	n/a (single transaction)
e)	Date of the transaction	2017-02-08
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr Urs Rohner
b)	Position/status	Independent Non-Executive Director
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Acquisition of notional Ordinary Shares following the annual reinvestment of dividends paid to shareholders throughout 2016 under the share allocation arrangements for Independent Non-Executive Directors.
c)	Price(s) and volume(s)	Price(s) Volume(s) £15.55 186.803
d)	Aggregated information Aggregated volume Price	n/a (single transaction)
e)	Date of the transaction	2017-02-08
f)	Place of the transaction	n/a

 

END

 

 

DSHDKLFBDLFXBBF